Ignite Creation Date:
2025-12-25 @ 2:40 AM
Ignite Modification Date:
2025-12-26 @ 6:45 PM
Study NCT ID:
NCT01604733
Status:
COMPLETED
Last Update Posted:
2012-05-24
First Post:
2012-05-21
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Centralized Pan-Middle East Survey on the Undertreatment of Hypercholesterolemia
Sponsor:
AstraZeneca
Organization:
Study Overview
Official Title:
Centralized Pan-Middle East Survey on the Undertreatment of Hypercholesterolemia
Status:
COMPLETED
Status Verified Date:
2012-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CEPHEUS
Brief Summary:
Study objective is to evaluate the level of control of hypercholesterolemia in Egypt in patients taking lipid lowering agents for at least 3 months ( with no drug change or dose amendment for a minimum of 6 weeks).
Detailed Description:
Centralized Pan-Middle East Survey on the Undertreatment of Hypercholesterolemia
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: